Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating COPD accompanied by pulmonary fibrosis

A composition and drug technology, applied in the direction of drug combination, antineoplastic drugs, pharmaceutical formulations, etc., can solve problems such as few literature reports, achieve good effect, improve lymphocyte transformation rate, and improve clinical symptoms

Inactive Publication Date: 2021-04-06
武汉金域医学检验所有限公司
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, some progress has been made in the treatment of pulmonary fibrosis with the combination of traditional Chinese and Western medicine, but there are few reports in the literature. After consulting the relevant literature, there is no report on the treatment of chronic obstructive pulmonary disease with pulmonary fibrosis and the prevention and inhibition of lung cancer.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating COPD accompanied by pulmonary fibrosis
  • Pharmaceutical composition for treating COPD accompanied by pulmonary fibrosis
  • Pharmaceutical composition for treating COPD accompanied by pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0020] 1. The pharmaceutical composition has obvious poisonous effect on A549 lung cancer cells. Experimental method:

[0021] Materials and methods

[0022] 1. Materials

[0023] The pharmaceutical composition is prepared by selecting the above-mentioned components (3 parts of Astragalus, 5 parts of Salvia, 5 parts of Scutellaria, 3 parts of Licorice, 5 parts of Safflower, 5 parts of Angelica, 5 parts of Tianding, 3 parts of Chuanxiong, Schisandra 3 parts, 5 parts Curcuma) Herbs were boiled and alcohol-precipitated to make a 1:10 extract; lung cancer A549 cell line was kindly provided by friendly people.

[0024] 2. Method

[0025] With reference to the method introduced in the literature, the lung cancer A549 cells were cultured in DMEM complete culture medium containing 10% fetal bovine serum (FBS), and adjusted to 4 × 10 5 / ml of cell suspension, inoculated in a 96-well plate, and 100ml of tumor cell suspension was added to each well. Add different concentrations of ex...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition for treating COPD accompanied by pulmonary fibrosis. The pharmaceutical composition comprises the following components in parts by weight: 3-15 parts of astragalus membranaceus, 5-20 parts of salviae miltiorrhizae, 5-15 parts of scutellaria baicalensis, 3-10 parts of liquorice, 5-15 parts of safflower carthamus, 5-15 parts of angelica sinensis, 5-20 parts of herba violae, 3-15 parts of ligusticum wallichii, 3-15 parts of schisandra chinensis and 5-20 parts of curcuma zedoary.

Description

technical field [0001] The invention belongs to the technical field of medicines, in particular to a pharmaceutical composition for treating COPD with pulmonary fibrosis. Background technique [0002] Pulmonary interstitial fibrosis (PF) is a chronic pulmonary interstitial disease. The basic pathological changes are pulmonary epithelial cell injury, inflammatory cell infiltration, fibrous tissue proliferation, and eventually pulmonary fibrosis, causing lung function damage and respiratory failure. Many diseases can cause pulmonary fibrosis, such as chronic obstructive pulmonary disease (COPD), the most common disease of the respiratory system, about 80% with fibrosis, pulmonary fibrosis, coronavirus infection such as the previous SARS, the current outbreak of COVID-19, anti-tumor Drugs, occupational dust and radiation and other factors. Pulmonary fibrosis may become the most serious complication after the epidemic. Therefore, for highly pathogenic coronavirus pneumonia, it ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/9066A61P11/00A61P35/00
CPCA61K36/232A61K36/236A61K36/286A61K36/481A61K36/483A61K36/484A61K36/537A61K36/539A61K36/57A61K36/79A61K36/9066A61K2236/331A61K2236/53A61P11/00A61P35/00A61K2300/00
Inventor 王成鑫杜娟吴玲敏王昀涂蕾阮景云唐春兰
Owner 武汉金域医学检验所有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com